Enzon Pharmaceuticals Inc.

Enzon Pharmaceuticals Inc.

Enzon Pharmaceuticals Inc.

Overview
Date Founded

1983

Headquarters

20 Kingsbridge Road,Piscataway, NJ 08854

Type of Company

Public

Employees (Worldwide)

11 - 50

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Industrial Machinery & Manufacturing
Biotechnology

Company Description

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company was founded on September 17, 1981 and is headquartered in Cranford, NJ.

Contact Data
Trying to get in touch with decision makers at Enzon Pharmaceuticals Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer & Secretary

Chief Executive Officer

Principal Financial Officer

Head of R&D

Director

Associate Director Quality Assurance

Associate Director Engineering

Network Administrator

Principal Financial Officer

Vice President

Board of Directors

President & Chief Executive Officer at Nevada Strategic Credit Investments LLC

Vice President/Taxes at The Icahn Medical Research Foundation

Vice President of Investor Relations & Strategy at Calithera Biosciences, Inc.

Paths to Enzon Pharmaceuticals Inc.
Potential Connections via
Relationship Science
You
Enzon Pharmaceuticals Inc.
Owners & Shareholders
Details Hidden

Poplar Point Capital Management LLC (PPCM) is a registered investment adviser headquartered in Burlingame, California and was founded in 2012. PPCM provides investment advisory services to individuals and institutional investors.

Details Hidden

HAM offers clients a fundamental, long-term oriented approach to investing which seek to provide strong risk-adjusted returns over time by focusing on undervalued securities and special situations. The firm manages equity portfolios or the equity portion of a balanced portfolio in a value style, seeking to purchase individual equities at significant discounts from intrinsic value. Their individual equity portfolios typically contain 15-40 individual holdings. HAM manages fixed income portfolios with a focus on loss aversion with respect to interest rate, inflation and credit risk.

Details Hidden

Poplar Point Capital Management LLC (PPCM) is a registered investment adviser headquartered in Burlingame, California and was founded in 2012. PPCM provides investment advisory services to individuals and institutional investors.

Recent Transactions
Details Hidden

Belrose Pharma, Inc. purchases Enzon Pharmaceuticals, Inc. /Pegylation Linker Tech Platform from Enzon Pharmaceuticals Inc.

Details Hidden

ESSETIFIN SpA, Leadiant Biosciences, Inc. purchase Enzon Pharmaceuticals, Inc. /Specialty Pharmaceutical Bus from Enzon Pharmaceuticals Inc.

Details Hidden

Enzon Pharmaceuticals Inc. purchases Elan Corp. Plc /Abelcet North American Operations from Elan Corp. Plc

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Investment Advisor

Advised onEnzon Pharmaceuticals Inc. purchases Elan Corp. Plc /Abelcet North American Operations from Elan Corp. Plc

Accountant

Advised onEnzon Pharmaceuticals Inc. purchases Elan Corp. Plc /Abelcet North American Operations from Elan Corp. Plc

Underwriter

Advised onEnzon Pharmaceuticals Inc. issued USD Common Stock

Legal Advisor

Advised onESSETIFIN SpA, Leadiant Biosciences, Inc. purchase Enzon Pharmaceuticals, Inc. /Specialty Pharmaceutical Bus from Enzon Pharmaceuticals Inc.

Legal Advisor

Advised onESSETIFIN SpA, Leadiant Biosciences, Inc. purchase Enzon Pharmaceuticals, Inc. /Specialty Pharmaceutical Bus from Enzon Pharmaceuticals Inc.

Advisors & Consultants
Consultant

Partner & Research Director at Barington Capital Group LP

Consultant

Chief Executive Officer at Enzon Pharmaceuticals Inc.

Consultant
Clients

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Key Stats and Financials As of 2019
Market Capitalization
$15.5M
Total Enterprise Value
$3.66M
Earnings Per Share
$-0.02
Revenue
$207K
Net Profit
$-980K
EBITDA
$-973K
EBITDAMargin
-470.05%
Total Debt
$0
Total Equity
$6.06M
Enterprise Value / Sales
17.69x
TEVNet Income
-3.74x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
-70.87%
Non-Profit Donations & Grants
Political Donations
$2,200
2001
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Enzon Pharmaceuticals Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Enzon Pharmaceuticals Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Enzon Pharmaceuticals Inc..